Modulation of cellular immune function in vitro by histamine receptor-bearing lymphocytes: mechanism of action

Effects of spirulina on the number of ovary mast cells in lead-induced toxicity in rats

The present study investigated the protective effect of Spirulina against the lead-induced increase in mast cells in the ovary during the oestrous cycle of rats. In the ovary cortex and medulla of lead-exposed animals, there was a significant increase in the number of mast cells; however, when also treated with Spirulina, a decrease was observed. The number of mast cells when Spirulina (300 mg/kg) was used alone was not significantly different from that of the control group. These results indicate that Spirulina decreases the number of mast cells induced by lead in the cortex and medulla of rat ovary.

Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial

OBJECTIVE

To evaluate the efficacy of oral cimetidine as a treatment for painful bladder disease (PBD, variously described as a 'symptom complex' of suprapubic pain, frequency, dysuria and nocturia in the absence of overt urine infection) by assessing symptom relief and histological changes in the bladder wall tissue components, compared with placebo.

PATIENTS AND METHODS

The study comprised 36 patients with PBD enrolled into a double-blind clinical study with two treatment arms, i.e. oral cimetidine or placebo, for a 3-month trial. Patients were asked to complete a symptom questionnaire (maximum score 35), and underwent cystoscopy and bladder biopsy before treatment allocation. On completing treatment the patients were re-evaluated by the questionnaire and biopsy. The symptom scores and bladder mucosal histology were compared before and after treatment, and the results analysed statistically to assess the efficacy of cimetidine.

RESULTS

Of the 36 patients recruited, 34 (94%) completed the study. Those receiving cimetidine had a significant improvement in symptoms, with median symptom scores decreasing from 19 to 11 (P < 0.001). Suprapubic pain and nocturia decreased markedly (P = 0.009 and 0.006, respectively). However, histologically the bladder mucosa showed no qualitative change in the glycosaminoglycan layer or basement membrane, or in muscle collagen deposition, in either group. The T cell infiltrate was marginally decreased in the cimetidine group (median 203 before and 193 after) and increased in the placebo group (median 243 and 250, P > 0.3 and > 0.2, respectively). Angiogenesis remained relatively unchanged. The incidence of mast cells and B cells was sporadic in both groups.

CONCLUSIONS

Oral cimetidine is very effective in relieving symptoms in patients with PBD but there is no apparent histological change in the bladder mucosa after treatment; the mechanism of symptom relief remains to be elucidated.

Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids

Salmeterol may be useful in the treatment of asthmatic patients requiring high-dose inhaled steroids, and there have been debates about its anti-inflammatory action. We have compared the efficacy and effects on serum inflammatory markers, including soluble interleukin 2R (sIL-2R), eosinophil cationic protein (ECP), and tryptase of salmeterol and albuterol in 20 patients with moderate to severe asthma who were all receiving high-dose inhaled corticosteroids and inhaled beta 2-agonist on demand. After a 2-week run-in period, they received, in a randomized, crossover, double-blind and placebo-controlled manner, either salmeterol, 50 micrograms twice a day, or albuterol 400 micrograms, four times a day, from a powder inhaler during two 2-week treatment periods, separated by a 2-week washout. Compared with albuterol, salmeterol treatment was associated with better morning and mean peak expiratory flow (p = 0.013 and 0.016, respectively), less daytime and nocturnal symptoms (p = 0.008 and 0.01, respectively), reduced requirement of rescue albuterol (p = 0.04), and better efficacy rating by patients (p = 0.04). However, serum concentration of sIL-2R was significantly higher during regular albuterol treatment (p = 0.014) but no differences were seen in the concentrations of ECP and tryptase between the two treatment periods. We conclude that inhaled salmeterol, 50 micrograms twice daily, confers a better control of asthma than albuterol, 400 micrograms four times daily, in patients with moderate to severe disease, and the latter treatment may be associated with increased T-lymphocyte activation.

Effects of adjuvants on bovine humoral and cellular responses to hypodermin A

Hypodermin A, a serine protease of the first-instar larva of the common cattle grub, Hypoderma lineatum (Villers), when formulated with complete Freund's adjuvant and administered to naive calves, will elicit protective immunity defined by an increase in in vivo larval mortality. This study evaluated two veterinary acceptable adjuvants, alhydrogel and amphigen (alone and in combination), for suitability as an adjuvant for hypodermin A. Complete Freund's adjuvant (CFA) is not an acceptable adjuvant for use because of adverse reactions at the injection site. The veterinary acceptable adjuvants were not as effective as CFA in inducing an antibody response as detected in the peripheral circulation. Of the adjuvants evaluated, the mixture of alhydrogel and amphigen induced the highest serum antibody response to hypodermin A. All adjuvants evaluated induced comparable immediate-type skin test responses, and the mixture of alhydrogel and amphigen was most comparable with CFA in terms of delayed-type skin reaction and resultant cellular infiltration at the reaction site. Although the mixture of alhydrogel and amphigen, when compared with CFA, did not elicit comparable levels of responsiveness in all parameters tested, the overall performance of the mixture suggests it to be worthy of further efficacy investigation in a vaccine formulation with hypodermin A.

In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients

We investigated the in vitro effects of famotidine on the cytotoxic activity of peripheral blood mononuclear cells (PBMC) and tumor-infiltrating lymphocytes (TILs). The cytotoxic activity of PBMC was augmented by famotidine at a concentration of 10 ng/ml, which is equivalent to the serum level achieved by the intravenous administration of a dose of 20 mg. This response to famotidine was seen only in cancer patients. Both the cytotoxic activity and DNA synthesis of activated TILs were increased by the combination of interleukin-2 and 1 microgram/ml of famotidine. Augmentation of cytotoxic activity by famotidine occurred independently of any decrease in the population of suppressor T-cells. Thus, famotidine may have the potential to be used in adoptive immunotherapy with TILs for cancer patients.

The effect of histamine on the immune response of hamsters to infection with Ancylostoma ceylanicum

The role of histamine in modulating the immune response of hamsters infected with Ancylostoma ceylanicum (hookworm) was investigated. Histamine administration (20 mg base/hamster x 6 ip) made the immune hamsters susceptible to challenge infection, and on assay the humoral as well as the cell-mediated responses were found to be suppressed. An adverse effect of histamine was observed on lymphocytes but the macrophage function remained unaltered, since the latter lack histamine receptors. These findings provide definite evidence that histamine suppresses specific immune responses, and that contrary to earlier reports this neurotransmitter does not play a direct role in the 'self-cure' phenomenon.

Cimetidine: an immunomodulator

Suppressor T lymphocytes possess histamine2 (H2) receptors and contribute significantly to the function of the immune system. Experimentally, cimetidine, an H2-receptor antagonist, has been shown to enhance a variety of immunologic functions both in vivo and in vitro because of its inhibitory effects on suppressor-cell function. Successful tumor immunotherapy, as well as some protection from infection, has been reported in experimental animals. Patients receiving cimetidine have been shown to exhibit enhanced cell-mediated immunity as evaluated by increased response to skin-test antigens, restoration of sensitivity following development of acquired tolerance, and increased responses of lymphocytes to mitogen stimulation. Preliminary reports also indicate that cimetidine may offer therapeutic benefits for patients with Varicella zoster and Herpes simplex infections, as well as those suffering from mucocutaneous candidiasis and common variable hypogammaglobulinemia. These immunoregulatory effects are dose-related but are not always consistent. Because of its inhibitory effect on suppressor function, cimetidine treatment may be deleterious in patients with organ transplant and autoimmune disorders. Cimetidine should be used as an immunomodulator on an experimental basis only.

Effects of capsaicin treatment on immunoglobulin secretion in the rat: further evidence for involvement of tachykinin-containing afferent nerves

Neonatal capsaicin treatment has previously been shown to diminish the primary antibody response of adult rats to the subcutaneously administered T-dependent antigen, sheep red blood cells, as measured using a modification of the Cunningham plaque-forming cell assay technique. We have now studied the kinetics of this response in adult normal, neonatally capsaicin-pretreated and neonatally capsaicin-pretreated substance P-infused rats, and examined the effects of the tachykinin antagonist Spantide, on the plaque-forming cell response. Capsaicin pretreatment did not affect the antigen-specific plaque-forming cell response over the first 4 days following antigen injection. At days 5, 6 and 7 of the response, there was a statistically significant decrease in the number of plaque-forming cells secreting antigen-specific IgM, an effect not observed in capsaicin-pretreated rats which were given a subcutaneous infusion of substance P at the time of antigen injection. The tachykinin antagonist Spantide inhibited the plaque-forming cell response in normal rats after in vivo infusion at the time of antigen injection by more than 70%. This effect of Spantide was dose dependent, occurred with maximal effect at 10 microM, and appeared to be independent of any histamine-mediated action. The results of this study provide further evidence for a receptor-mediated immunomodulatory role of tachykinin-containing primary afferent nerves.

Modulation of canine lymphocyte blastogenesis via histamine

The effect of histamine on in vitro T cell blastogenic responses of canine peripheral blood lymphocytes to phytohemagglutinin-P (PHA-P) was investigated. A dose dependent inhibition of blastogenesis was observed; an effect which could be blocked by cimetidine, a type II histamine receptor antagonist, but not by diphenhydramine, a type I receptor antagonist, suggesting that histamine's inhibitory effect is mediated through a type II histamine receptor. The inhibitory effect of histamine on blastogenesis was also reversible by indomethacin, a prostaglandin synthetase inhibitor, implicating prostaglandin involvement in histamine suppression. Histamine release at sites of inflammation may result in down regulation of local immune responses by activation of specific immunoregulatory cells. This could permit the escape of certain neoplasia from local immunosurveillance mechanisms. Cimetidine may block activation of histamine responsive regulatory cells bearing type II receptors, which may help explain the beneficial effect cimetidine therapy has on regression of certain human tumors (i.e., malignant melanomas).

Immunoregulation of human natural killer cells (NK) by corticosteroids: inhibitory effect of culture supernatants

Peripheral blood lymphocytes were separated into HNK-1+ and HNK-1- subpopulations and examined for the effects of prednisolone (PRD) on natural killer cell activities in vitro. Preculture of HNK-1+ lymphocytes with PRD (10(-6) to 10(-8) mol/L) for 72 hours resulted in a significant reduction of cytotoxic functions. When peripheral blood lymphocytes were first precultured with PRD and then separated into HNK-1+ and HNK-1- subpopulations, both could suppress the target binding and lytic activities of fresh large granular lymphocytes with the HNK-1+ cells demonstrating greater inhibition than the HNK-1- cells. Moreover, PRD-treated cells demonstrated greater suppression of target binding and cytotoxicity than identical subpopulations cultured without PRD. Culture supernatants of lymphocytes treated with 10(-6) to 10(-9) mol/L concentrations of PRD contain PRD-induced soluble suppressor factor that significantly inhibited the natural killer activity of allogeneic lymphocytes against different targets. PRD-induced soluble suppressor factor was not cytotoxic itself, and suppression was evident at various effector-to-target cell ratios. These studies indicate that in addition to being directly immunosuppressive, corticosteroids may also induce immunoregulatory lymphocytes to secrete a suppressive lymphokine.

Distribution and ultrastructure of mast cells in the equine respiratory tract

Mast cells in the equine respiratory mucosa were studied at both light--and transmission electron--microscope levels. Mast cells were identified at all levels of the tract, with the greatest cell density in the nasopharynx. The majority (57 to 94 per cent) of this cell population were located within the connective tissue of the lamina propria. Up to 20 per cent of these cells were associated with the mucosal glandular tissue, whilst small numbers were present within the surface epithelium and in association with nodular lymphoid tissue. In the peripheral lung tissue 20 per cent of the mast cell population was associated with the small airways, 25 per cent with the pleura, and 32 per cent with blood vessels. The fine and ultrastructural features of these mast cells resemble those described in other species, and their granules consist of two types which resemble human mast cells.

Immunologic effects of cimetidine: potential uses

Suppressor T lymphocytes play a major regulatory role in the function of the immune system. Since the discovery of histamine (H2) receptors on the surface of these immune cells, studies have demonstrated that cimetidine diminishes the effect of suppressor T cells in both cellular- and humoral-mediated (antibody) immune reactions. Preliminary clinical results demonstrate that cimetidine has a beneficial effect on a variety of immune functions. An antineoplastic effect among tumor-bearing animals has also been found, suggesting the drug may be effective against certain human cancers, probably as an immune potentiator. Cimetidine has been used in the treatment of human cancer in combination with interferon or coumarin and as a single agent. Modest tumor response rates have been observed. The finding that cimetidine accelerates healing of herpesvirus infections is intriguing. These encouraging, albeit preliminary, results emphasize the need for additional studies on the drug's antiviral properties.

Evidence for serotonin (5HT) binding sites on murine lymphocytes

The binding of 3H-labeled serotonin (or 5-hydroxytryptamine: 5HT) to mouse lymphocytes was investigated. It was shown to be highly specific, time-dependent, saturable and partly reversible. Saturation analysis demonstrated a Kd of 198 nM and B max of 3.53 nM. We studied receptor specificity by using different types of serotonin antagonists, and numerous other substances. Serotonin was found to be the most effective drug among those tested in inhibiting the binding of 3H-5HT, having an IC50 of 194 nM. The fact that 5HTP, a 5HT precursor, had no inhibitory capacity indicated the high specificity of these 5HT binding sites. Dopamine was somewhat able to competitively inhibit 5HT fixation (IC50 = 27,000 nM), whereas norepinephrine and histamine had no effect. Lastly, we investigated the cellular specificity of this binding, and observed that nonmacrophage peritoneal cells extensively bound serotonin under the same conditions as spleen cells. This is the first direct demonstration of 5-hydroxytryptamine receptors on mouse lymphocytes. The presence of these binding sites can contribute to the understanding of the suppressive effect of 5HT on mouse immunoreactivity.

Intestinal immunity and inflammation: recent progress

The previous sections illustrate that we are still defining (a) which sets of lymphoid cells are present in the intestine and which are not, (b) which sets are peculiar to the intestine, and (c) how the sets that are there function in the intestinal microenvironment. An understanding of the latter point is going to require knowledge of how these sets communicate with and regulate one another via cell surface molecules such as MHC class I and class II molecules, and via soluble mediators or lymphokines. The recent advances in various technologies make this a particularly exciting time in this field because the tools are now available to address and answer some of these basic and important questions in mucosal immunology. At the same time these advances hold great promise for our eventual understanding of chronic inflammatory diseases of the intestine. As was mentioned at the outset, the immune system has considerable power for both protection and destruction. It remains a puzzle how this latter potential is contained and controlled in the intestine of most individuals, such that they do not have inflammatory disease even in the setting of intense stimulation by substances, such as endotoxin, that are phlogistic elsewhere in the body. An answer to the question of why everyone does not have intestinal inflammation could provide new insights into the mechanisms involved in chronic intestinal inflammatory diseases. The recent advances just detailed, as well as others sure to come, suggest that it is only a matter of time before such questions are answered.

Solubilization and characterization of a low-affinity histamine-binding site on human blood mononuclear cells

The extract of human peripheral blood lymphocytes and monocytes treated with Triton X-100, in direct- and competitive-binding studies, with 10(-6)-10(-2) M [14C]histamine contained a low-affinity binding site whose dissociation constant (Kd 1.8 X 10(-4) M) was commensurate with the concns of histamine (10(-6)-10(-3) M) that result from mast cell and basophil degranulation. Binding was enhanced by millimolar concns of divalent cations and by raising the incubation temp from 4 to 37 degrees C. It was inhibited by trypsin, EDTA, agents interacting with thiol groups, and by Triton X-100 concns greater than 0.2%. Thus a low-affinity histamine receptor that maintains its ligand-binding properties after solubilization from the cell surface was identified.

The regulatory effect of histamine on the in vitro synthesis of IgE

The effect of histamine and its H1 and H2 antagonists, chlorpheniramine and cimetidine, on the in vitro, PWM-induced, synthesis of IgG and IgE was studied. Histamine had no effect, and cimetidine had a slight inhibitory action. In contrast, chlorpheniramine induced marked suppression of both IgE and IgG synthesis. This effect could not be attributed to drug-induced cytotoxicity. These results suggest that the modulatory effect of histamine on antibody production involves predominantly H1 receptors.

Increase in skin mast cells following chronic house dust mite exposure

Application of inhalant allergens in high concentration to the mildly abraded skin of sensitive patients with atopic dermatitis gave rise to eczematous skin responses at 48 h. These lesions, infiltrated by basophils, eosinophils and mononuclear cells, are examples of cutaneous basophil hypersensitivity. Repeated application of allergen induced an increase in skin mast cells by 6 days, the mast cell hyperplasia replacing the earlier basophil infiltration. No electron microscopic evidence of mast cell heterogeneity among the recruited cells was found.

Effect of H1 and H2 agonists on the chemiluminescence of human blood mononuclear cells induced by phytohaemagglutinin

Previous results have shown a dose-dependent inhibition of the phytohaemagglutinin-elicited chemiluminescent response by histamine on human peripheral blood mononuclear cells (PBMs). The aim of the present experiments was to investigate the receptor specificity of this histamine action. The order of effectiveness of different histaminergic agonists was 4-methylhistamine greater than histamine = impromidine greater than dimaprit much greater than 2-methylhistamine greater than 2-pyridylethylamine. Cimetidine inhibited and mepyramine enhanced this effect of histaminergic agonists. The results are consistent with the view that histamine inhibits the chemiluminescent reaction of PBMs via H2 receptors. Histamine in low doses (10(-8) to 10(-10) M) stimulated the chemiluminescent reaction. Cimetidine enhanced the chemiluminescence-facilitatory action of histamine and unmasked that of 2-pyridylethylamine. It is concluded that histamine is a possible humoral modulator of PBM activity: it is inhibitory via H2 receptors.

Human lymphocyte-eosinophil interactions. I. Modulation of phytohemagglutinin-induced lymphocyte proliferation by eosinophils

Do eosinophils modulate lymphocyte function? This question was studied by examining the effect of purified eosinophils (eos) on lectin-induced human lymphocyte proliferation. Intact resting or zymosan-stimulated eos or their extracts were cocultured with phytohemagglutinin-stimulated mononuclear cells in vitro and [3H]thymidine uptake was measured at 72 hr. Zymosan-stimulated eos consistently suppressed (up to 90%) the lectin-induced proliferative response by a noncytotoxic mechanism. Freeze-thaw extracts from zymosan-stimulated eos also significantly suppressed lymphocyte proliferation to a similar degree. The amount of suppression was directly proportional to the number of eos or the amount of extract added to the lymphocyte cultures. Intact resting eos and their extracts occasionally exhibited suppressive effects (up to 40%) on lymphocyte proliferation; this suppression, however, was always less than that of activated eos or their extracts. Eos pretreated with the protein synthesis inhibitor, pactamycin, exhibited significantly less suppressive activity, suggesting that a protein was responsible in part for the reduction in proliferation. The addition of superoxide dismutase or catalase to the eos-mononuclear cell cocultures did not reduce the amount of suppression observed, thus making it unlikely that active oxygen products were involved in the mechanism of suppression. Heating extracts from stimulated eos to 80 degrees C for 30 min resulted in partial loss of suppressive activity while extensive dialysis of the extracts had no effect. The studies reported here provide evidence that a nondialyzable and heat sensitive factor(s) produced by stimulated eos may exert feedback inhibition of lymphocyte function.

Cellular origin of human lymphotoxin and its purification

The ability of various subsets of human mononuclear cells to produce human lymphotoxin (LT) was examined. Peripheral blood mononuclear cells were separated into OKT4+, OKT8+, and Leu-11a+ subpopulations by flow cytometry. Both OKT4+ and OKT8+ cells produced LT upon phytohemagglutinin (PHA) stimulation, but the OKT4+ T cells were the major source of LT. In contrast, Leu-11a+ cells failed to produce LT. The LT production and the proliferative response to PHA, of OKT4+ and OKT8+ cells, were inhibited by prostaglandin E2 and histamine. The LT, derived from PHA-stimulated peripheral blood lymphocytes, was purified by a procedure involving Blue-agarose, Con A-Sepharose chromatography, preparative gradient polyacrylamide gel electrophoresis and preparative sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The LT activity was recovered from SDS gel with major activity peak in the Mr 76,000 region and the minor activity peak in the Mr 24,000 region. The LT derived from 1788 lymphoblastoid cell line also showed heterogeneity on SDS gel. The activity was recovered from two peaks in the region of Mr 70,000 and 20,000.

Characteristics of histamine receptors present on suppressor T cells in "healthy individuals"

Twelve to 30% histamine receptor bearing cells were detectable in the peripheral blood mononuclear cells of healthy tuberculin sensitive individuals. The number of binding sites per cell ranged from 2.1 X 10(4) to 5.08 X 10(4) (mean 2.5 X 10(4)) with an affinity ranging from 2.5 X 10(-6) M to 10.9 X 10(-6) M (mean 3.6 X 10(-6) M). The histamine receptors on these cells were found to be of H2 type as indicated by the abrogation of binding of 3H-histamine by cimetidine. It was further confirmed that histamine receptor bearing cells in the peripheral blood belonged to a T cell subset which formed rosettes with AET treated sheep erythrocytes and had receptors for Fc portion of IgG and phenotype markers of T3 and T8. Deletion of such cells by means of affinity chromatography on histamine bound Sepharose columns, led to enhanced antigen induced lymphoproliferation indicating the suppressor nature of these T cells.

Control of polyclonal immunoglobulin production from human lymphocytes by leukotrienes; leukotriene B4 induces an OKT8(+), radiosensitive suppressor cell from resting, human OKT8(-) T cells

We report that leukotriene B4 (LTB4), a 5-lipoxygenase metabolite of arachidonic acid, is a potent suppressor of polyclonal Ig production in pokeweed mitogen (PWM)-stimulated cultures of human peripheral blood lymphocytes, while LTC4 and LTD4 have little activity in this system. Preincubation of T cells with LTB4 in nanomolar to picomolar concentrations rendered these cells suppressive of Ig production in subsequent PWM-stimulated cultures of fresh, autologous B + T cells. This LTB4-induced suppressor cell was radiosensitive, and its generation could be blocked by cyclohexamide but not by mitomycin C. The LTB4-induced suppressor cell was OKT8(+), while the precursor for the cell could be OKT8(-). The incubation of OKT8(-) T cells with LTB4 for 18 h resulted in the appearance of the OKT8(+) on 10-20% of the cells, and this could be blocked by cyclohexamide but not by mitomycin C. Thus, LTB4 in very low concentrations induces a radiosensitive OKT8(+) suppressor cell from OKT8(-) cells. In this regard, LTB4 is three to six orders of magnitude more potent than any endogenous hormonal inducer of suppressor cells previously described. Glucocorticosteroids, which block suppressor cell induction in many systems, may act by inhibiting endogenous production of LTB4.

Antigen specific suppressor cell function in autoimmune chronic active hepatitis

An indirect migration inhibition assay has been used to show that lymphocytes from 26 of 29 patients with autoimmune chronic active hepatitis (CAH) generated T lymphocyte migration inhibitory factors (T-LIF) in the presence of liver specific protein (LSP), compared with only 1 of 21 patients with HBsAg-positive chronic liver disease and none of 19 controls. Generation of T-LIF activity in response to LSP was not observed in any of 5 patients with autoimmune thyroid disease although their T lymphocytes did generate T-LIF activity in the presence of thyroid membrane antigens. T lymphocytes from 1 patient with autoimmune liver and thyroid disease generated T-LIF activity in the presence of both LSP and thyroid membrane antigens. The generation of T-LIF activity by T cells from autoimmune CAH patients was suppressed when these cells were co-cultured in a 9:1 ratio with T cells from normal subjects and patients with HBsAg-positive chronic liver disease, but was unaffected if co-cultured with T cells from other patients with autoimmune CAH. T cells from patients with autoimmune CAH did, however, suppress the generation of T-LIF activity by T lymphocytes from patients with autoimmune thyroid disease when these cells were cultured with thyroid membrane antigens. After pretreatment with cimetidine or mitomycin-C for 30 min, T cells from normal subjects lost their ability to inhibit the generation of T-LIF activity to T lymphocytes from autoimmune CAH patients. These results are consistent with the hypothesis that there exists a defect in the specific suppressor T cell population controlling the immune response to LSP in autoimmune CAH which is unaffected by disease activity and treatment and which may be of fundamental importance in the pathogenesis of the disease.

Histamine and serotonin suppression of lymphocyte response to phytohemagglutinin and allogeneic cells

Histamine added to murine spleen cells suppressed in vitro proliferation of lymphocytes induced by PHA or allogeneic spleen cells. Another vasoactive amine, serotonin (5-hydroxytryptamine), exerted a similar inhibitory activity on PHA- or allogeneic cell-induced lymphocyte proliferation. Anti-H2 histamine antagonists, cimetidine, metiamide, and ranitidine, blocked the histamine and serotonin suppressive effect. Cyproheptadine, an anti-H1 histamine and anti-serotonin antagonist, and methysergide, an anti-serotonin antagonist, also blocked histamine and serotonin inhibitory activities. These data suggest the presence, on lymphocytes, of receptors for serotonin which might be related to histamine receptors.

The effect of cimetidine treatment on suppressor T cells in duodenal ulcer patients

Changes in the suppressor T-lymphocyte activity were studied in 11 patients with duodenal ulcer during treatment with cimetidine. The drug was administered intravenously in a dose of 200 mg four times a day for a fortnight. Suppressor T-cell activity was determined by the Shou et al. method using two-stage culture before treatment, after 4 days of the treatment, just before drug withdrawal, and 2 days and 2 wk after the treatment. Suppressor T-cell activity significantly decreased soon after starting the treatment, remained low throughout the treatment, and rapidly and significantly increased following drug withdrawal.

Contrasuppression: the second law of thymodynamics, revisited

The data discussed here touch upon several issues in the evolving story of T cell contrasuppression, the underlying theme being that of heterogeneity. First, there is the issue of function. We are considering here only those cells that affect the function of secretory differentiation. We have evidence that different contrasuppressor cells exist for clone growth, but have not yet studied them in the same depth as those for secretory differentiation. Second, there is the important issue of target cells. In this article by Green and Gershon it is pointed out that there is clear evidence that contrasuppressor effects can work by protecting helper cells from suppressor cell effects in vitro. On the other hand, direct additional inhibition of the suppressor cells themselves has not been excluded. The latter point is also true in our system. However, we must suppose for the sake of simplicity in many of our experiments that if suppressors are not the target of the contrasuppressor effects then the B cells themselves probably are. This is because the tumor cells engage in a spontaneous rate of growth and differentiation in the absence of help or suppression. When T cell-dependent, specifically triggered effects reduce this spontaneous behavior, then a suppressive effect must have been delivered directly to the B cells. This is a simplifying assumption which is attractive, but since the experiments are carried out in vivo and thus may be affected by some factors that we have not yet recognized, we are not confident on its "intuitive" appeal. A third issue revolves around triggering specificity. One of our contrasuppressors exhibits the phenomenon of carrier crossreactivity (CRCS) and is thus behaving in accord with expectations aroused by Green and Gershon in this review. The other cell is apparently quite carrier specific (SCS). The meaning of this is not at all clear, but its potential significance may somehow be related to a sort of "mirror image" relationship of the two cells. Thus, for example, in other experiments not discussed here, we have noted that the CRCS binds to 315 protein-coated plates, but as noted here counteracts a suppressive effect which is generated by cells which do not adhere to these plates. In contrast to SCS does not bind to 315 plates and yet, as noted here, appears to counteract a suppressor effect generated by cells which do adhere to 315 plates.(ABSTRACT TRUNCATED AT 400 WORDS)

Antimetastatic effect of cimetidine on mice bearing a C3H mouse mammary adenocarcinoma: survival and lymphocyte function studies

It has been reported that treatment with cimetidine, a histamine H2-receptor antagonist, increased survival and decreased the number of lung metastases in mice bearing the Lewis Lung carcinoma [29]. It was suggested that this effect was due to the ability of cimetidine to block histamine activation of suppressor lymphocytes and hence allow host defence mechanisms to inhibit tumour growth. In the present studies, C3H/He mice were implanted with a C3H mouse mammary adenocarcinoma on Day 0. This tumour metastasizes to the lungs in 30-50 days. Primary tumours were ablated with X-rays when they had grown to about 0.2 g and animals were given drinking water with or without cimetidine (10 mg ml-1) until the end of the experiment. Cimetidine reduced the number of mice dying from metastatic disease from 7/15 (controls) to 3/13. Cimetidine treatment also prolonged survival of mice that did succumb to metastatic disease by about 12 days. The response of spleen lymphocytes to the mitogens phytohaemagglutinin and lipopolysaccharide was assessed in vitro by uptake of 3H-thymidine 0, 16, 45 and 58 days after tumour implantation. Lymphocyte responsiveness was depressed by tumour burden. The influence of cimetidine treatment was equivocal being dependent upon time after tumour implantation and dose of mitogen. In this mouse-tumour system, the mechanism of the antimetastic effect of cimetidine is different from that previously suggested [29].

Basophils in human disease

Hypersensitivity reactions containing significant infiltrates of basophils occur in a large proportion of allergic diseases such as contact dermatitis, atopic dermatitis, and allergic rhinitis, and are quite deleterious. However, the potential usefulness of such responses can be recognized in similar reactions in guinea pigs responding to tissue invasion by complex multicellular parasites in which interactions occur between thymic-derived T lymphocytes, antibodies, and basophils in immune resistance responses. Perhaps inappropriate and deleterious allergic responses to pollens, chemicals, and insects is the price that we must pay for the ability to reject complex parasites.

The effect of cimetidine on immunological parameters in Crohn's disease: a double blind trial

Thirty-six patients with Crohn's disease were entered into a double-blind trial to assess any beneficial effect that cimetidine might have on immunological and clinical status. Eighteen patients were randomized to receive cimetidine, 1 g orally for 28 days, and the other 18 patients to receive a placebo. There was no alteration in clinical status in the cimetidine-treated group. Although 64% of the patients were anergic, augmentation of skin tests to candida, mumps, tuberculin, streptokinase/streptodornase and trichophyton antigens, was not observed in the cimetidine-treated patients. The patients with Crohn's disease, as a whole had higher absolute numbers of suppressor T-lymphocytes, 0.70 X 10(9)/litre (0.21-2.36, n = 35) compared to control values, 0.5 X 10(9)/litre (0.16-1.55, n = 25) (P less than 0.05). However, there was no significant difference in proportions of suppressor and helper T-lymphocytes, lymphocyte activation and humoral immunity after cimetidine treatment. The lack of any clear modulation of immunity by cimetidine, would be against trying H2 antagonists in a long term clinical trial.

A study of histamine release from human basophils and lung mast cells by products of lymphocyte stimulation

It has been previously reported by Thueson and his co-workers [1] that lymphokine-containing supernatant of cultured human peripheral blood lymphocytes stimulated with Concanavalin-A (Con-A) is capable of releasing histamine from human basophils. Here we confirm such findings, show that such release is additive to that due to immunological stimuli (Anti-IgE and antigen) and describe its characteristics and effect in lung tissue. The lymphokine was found to induce a small histamine release from chopped or enzyme-dispersed human lung tissue. As was the case with basophils, the release from lung tissue by this factor, though small, was also found to be additive to that induced by anti-IgE when both agents were added simultaneously. Histamine release from leucocytes by neat supernatant ranged from 9 to 35% and up to 55% when concentrated four-fold. The release resembled that of IgE-mediated reactions in many respects including temperature and calcium dependence, time course and susceptibility to metabolic inhibitors - thus suggesting a non-cytotoxic mechanism. These results show that histamine release by this lymphokine(s) possesses most of the features of an active secretory process. They also suggest that the histamine-releasing factor (HRF) in lymphokine-containing supernatants might be involved in the modulation of type I allergy in humans, apart from its involvement in delayed-type hypersensitivity.

In vitro effects of certain polycyclic aromatic hydrocarbons on mitogen activation of mouse T-lymphocytes: action of histamine

T lymphocytes were isolated from the spleens, thymuses, and bone marrow of three inbred mice strains, and the effects of two carcinogenic polycyclic aromatic hydrocarbons (PAH) on the mitogen activation of these cells were assessed. Benzanthracene (BA) and 3-methylcholanthrene (MCA) enhanced mitogen activation of splenic T cells in a strain-related fashion: C3H greater than C57BL greater than DBA/2 (P less than 0.025). This pattern of strain relatedness was not observed in T cells from the other lymphoid organs. Mitogen activation was suppressed by histamine to a greater degree in T cells from PAH-responsive mice (C3H and C57BL) than in the nonresponsive strain (DBA/2). Histamine inhibited rosette formation between T cells and histamine-conjugated sheep red blood cells. A histamine suppressor factor (HSF), isolated from splenic lymphocytes grown in the presence of histamine or histamine plus MCA, was significantly higher in activity in culture supernatants from T cells derived from responsive mice than from nonresponsive mice. With the use of Lyt 1 and Lyt 2 monoclonal antibodies, it is shown that the baseline percentage of T helper and T suppressor cells was not significantly different in all three strains. Further, histamine and MCA had no effect on the expression of the Lyt 1 and Lyt 2 surface antigens on splenic lymphocytes. These results suggest that PAH-responsive mice may have more T-cell H2 receptors than T cells from nonresponsive mice. Histamine and PAH compounds may act on the same T-cell subsets, as evidenced by the fact that BA and MCA enhance blastogenesis, histamine suppresses mitogen activation, and these PAH compounds enhance histamine and HSF activity.

Physiochemical characterization of human histamine-induced suppressor factor

A product of histamine-stimulated human lymphocytes, histamine-induced suppressor factor or HSF, was characterized by enzyme treatment, sensitivity to reduction and alkylation, by molecular sieve chromatography, and by polyacrylamide gel electrophoresis. HSF was found to have a wide pH stability (pH 3-10), sensitivity to temperatures greater than 80 degrees C, and to have the properties of a glycoprotein by virtue of its sensitivity to chymotrypsin, trypsin, sodium periodate, and neuraminidase. HSF did not appear to have a serine group(s) in its "active" site since its biologic activity remained intact following treatment with an irreversible serine esterase inhibitor (phenylmethylsulfonyl fluoride). Further, HSF did not appear to have inter- or intra-molecular disulfide linkages because treatment with denaturing and/or reducing agents, followed by alkylation, did not significantly alter its activity. Molecular sieve chromatography employing Sephadex G-100 revealed an apparent molecular weight for HSF of 25-40,000. Electrophoresis of HSF in polyacrylamide gels at pH 8.7 under nonreducing conditions revealed two regions of activity, one region migrating with albumin and the other region anodal to albumin. In addition to suppressing lymphocyte proliferation, the 25-40,000 Mr Sephadex G-100 fractions also inhibited the production of leukocyte inhibitory factor. Of particular interest, gel filtration of supernatants generated by stimulating mononuclear cells with either histamine, dimaprit (but not 2-pyridylethylamine), concanavalin A, or candida albicans resulted in similar elution profiles with regard to inhibition of lymphocyte proliferation. That is, 25-40,000 Mr fractions of supernatants generated by each stimulant suppressed lymphocyte proliferation to a similar degree. The latter findings provide indirect evidence that T lymphocytes, triggered in response to antigen-specific and nonspecific stimuli, elaborate suppressor molecules capable of modulating T-cell function that share certain similarities.

Cimetidine and the immune response. I. In vivo augmentation of nonspecific and specific immune response

Cimetidine is a commonly prescribed histamine antagonist useful in the treatment of peptic ulcer disease. Histamine receptors are found on suppressor T cells and therefore we expected to observe enhanced immune responsiveness in animals treated with this drug. Mice given daily subcutaneous injections of cimetidine (25 or 100 mg/kg) were found to produce approximately twice as much specific antibody in response to tetanus toxoid immunization. Furthermore, mitogen-stimulated splenocytes from cimetidine-treated animals proliferated to a greater extent and produced more immunoglobulin in vitro than controls. These observations offer direct in vivo evidence for immunomodulation by cimetidine.

The effect of histamine on the development of adjuvant arthritis in the rat

Histamine, injected subcutaneously (0.3-10 mg/kg), produced a dose-related inhibition of the primary and secondary inflammation, and the development of the secondary lesions of rat adjuvant arthritis. Histamine was effective when given for short periods around the time of adjuvant administration and could also delay and possibly reverse an established arthritic response. The histamine H1-agonist, 2-(2-pyridyl)-ethylamine, inhibited rat adjuvant arthritis, whereas the histamine H2-agonists, impromidine and dimaprit, failed to affect the response. Metiamide, a histamine H2-antagonist (5 mg/kg), reduced the inflammation in the uninjected hind-paw and the development of secondary lesions. Histamine may have two effects on rat adjuvant arthritis, inhibiting the response via stimulation of H1-receptors and augmenting the response via stimulation of H2-receptors. Since histamine is known to bind to and to alter the reactivity of cells which are involved in the regulation of immune responsiveness, it is suggested that interactions with these cells are responsible for the observed effects of histamine.

T-cell suppression and contrasuppression induced by histamine H2 and H1 receptor agonists, respectively

The intensity of Lyl+T helper and delayed type hypersensitivity effector cell activities is governed, in part, by an interplay between two classes of immunoregulatory T cells: suppressor cells and contrasuppressor cells. We asked whether histamine, at concentrations and duration of exposure that we calculated might be achieved at local sites of inflammation, could activate either or both of these classes of regulatory cells in vitro. To answer this question we used spleen cells from mice treated in vivo with the toleragen trinitrobenzenesulfonic acid as regulators of in vitro generation of primary anti-trinitrophenyl self-cytotoxic T lymphocytes. Under the conditions used, these spleen cells had no major regulatory effects. However, if these cells were preincubated with histamine at 0.1 mM for 30-60 min, suppressor activity was induced, but this occurred inconsistently and with nonstoichiometric results. The use of synthetic histamine agonists revealed that histamine may activate both suppressor and contrasuppressor cell subsets. A histamine H1 receptor agonist [2-(2-pyridyl)-ethylamine dihydrochloride] had a propensity to activate contrasuppression, whereas an H2 receptor agonist (dimaprit) tended to activate suppressor cells. Thus, histamine may have opposing actions that obscure suppression. This duality was shown by treatment of pyridylethylamine-induced contrasuppressor cells with complement and anti-I-J antibody that kills contrasuppressor cells. This treatment revealed a high level of suppressor cell activity that was not expressed until the opposing contrasuppressor cells were removed. Because histamine is released at local sites of delayed type hypersensitivity, these results indicate that histamine may serve as an inducer of microenvironmental immunomodulation by activating regulatory T cells at sites where immune responses are taking place.

Regulation of in vitro cytotoxic T lymphocyte generation. II. Demonstration of noncytotoxic alloantigen-specific suppressor T lymphocytes

Both allospecific suppressor T lymphocytes (TsS) and nonspecific suppressor T lymphocytes (TsN) are activated in alloantigen-stimulated mixed leukocyte cultures (MLC). TsS and TsN can suppress cytotoxic T lymphocyte (CTL) induction upon transfer to fresh (second) MLC stimulated by the same alloantigens as in the first MLC (TsS or TsN) or by third-party alloantigens (TsN only). Evidence that TsS and TsN functions are performed by different T cell sets has been restricted to radioresistance of the former but not the latter. Separation of TsS from CTL has proven even more difficult. Methods are reported here which have allowed in vitro induction and functional separation of TsS from CTL and TsN in a totally allogeneic system. TsS are resistant to combined exposure to pyrilamine, a histamine1 antagonist and local anesthetic, during suppressor cell induction, and to X or gamma irradiation thereafter, while CTL precursors (CTL-P) and TsN are more sensitive to such treatments. This allowed us to use these treatments to generate TsS that are not contaminated with functional CTL, CTL-P or TsN. These data show that TsS regulate CTL induction by interacting with responding cell populations, rather than by cytotoxic depletion of stimulator cells.

Augmentation of concanavalin A-induced immunosuppression by indomethacin

These studies show that, in BALB/C mice, when antibody synthesis against sheep red blood cells is suppressed by concanavalin A, treatment with indomethacin (4-8 mg/kg per os) will augment this suppression. Two other nonsteroidal anti-inflammatory drugs, flufenamic acid and meclofenamic acid (50 mg/kg), also have this effect, whereas phenylbutazone was inactive at this dose. The augmentation of concanavalin A-induced immunosuppression by indomethacin could not be demonstrated on the response to the T-independent antigen polyvinypyrrolidone. In contrast to indomethacin, which inhibits cyclooxygenase, neither nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, nor eicosa-5,8,11,14-tetraynoic acid, an inhibitor of both the cyclooxygenase and the lipoxygenase pathways, had this augmenting effect. Therefore, we do not have strong evidence that the absence of a prostaglandin is responsible for the effect of indomethacin. However, inhibition of the pathway leading to prostaglandin synthesis causes an increase in arachidonic acid metabolism via the lipoxygenase pathway. A product of this pathway, such as a leukotriene, may have immunosuppressive effects in this model. Evidence for the enhancement of a suppressor cell population is provided by an in vitro coculture assay. Cells treated with concanavalin A and indomethacin had more suppressive activity than cells treated with concanavalin A or indomethacin alone.

Effect of selected immunoregulatory agents on low-grade contact sensitivity

The effect of selected compounds with known immunoregulatory activity was examined in a 45-h sensitization period oxazolone contact-sensitivity reaction. Oxazolone sensitivity was induced by applying 0.1 ml of 5% oxazolone in absolute ethanol to the shaved abdomen of C57Bl/6 mice on day 0. Challenge with oxazolone followed 45 h later and was accomplished by painting a 5% solution of oxazolone in absolute ethanol on the left hindpaw. The response at 24 h was determined plethysmographically. Histamine (0.062-1.0 mg/kg, subcutaneously, twice a day), concanavalin A (0.31-5.0 mg/kg intravenously), penicillamine (6.25-25 mg/kg, subcutaneously), chloroquine (6.25-25 mg/kg, subcutaneously), and thymosin fraction 5 (0.125-1.25 mg/kg subcutaneously) all stimulated the oxazolone reaction when administered on day 0. These data suggest that the low-grade oxazolone response may be a useful assay to detect immunostimulatory activity.

Allosuppressor T lymphocytes abolish migration inhibition factor production in autoimmune thyroid disease: evidence from radiosensitivity experiments

The ability of normal T lymphocytes to abolish the production of migration inhibition factor by antigen-sensitized T lymphocytes of Graves' disease (GD) and Hashimoto's thyroiditis (HT) in response to thyroid antigen has been studied by a modified migration inhibition factor test using isolated T lymphocytes alone. The production of migration inhibition factor was consistently abolished when normal T lymphocytes were mixed with GD or HT T lymphocytes in various ratios (1:9, 2:8, 5:5) as reported previously (Okita et al. 1980b). However, prior in-vitro irradiation (1000 rad) of the normal T lymphocytes resulted in loss of their ability to abolish migration inhibition factor production by the antigen-sensitized T lymphocytes of GD and HT. The effect is consistent with the radiosensitivity of suppressor T lymphocytes and indicates that the effect of normal T lymphocytes on GD and HT T lymphocytes is one of allosuppression. The results support the view that there is a defect in suppressor T cell function in GD and HT.